

# Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

## Frontiers in Digestive Research and Practice

<b>Name</b>	Jin-Soo Kim
<b>Affiliation</b>	Seoul National University Boramae Medical Center
<b>Country</b>	Rep. of Korea
<b>Major Field</b>	Medical Oncology

### Educational Background

February 2005 ~ February 2014 (PhD)

The doctor's course (PhD) in Department of Molecular Oncology, Seoul National University, Seoul, Korea (Mentor: Prof. Yung-Jue Bang)

Doctoral dissertation: Resistance Mechanism to Histone Deacetylase Inhibition in Non-small Cell Lung Cancer

March 2003 ~ February 2005 (MS)

The Master's course in Department of Molecular Oncology, Seoul National University, Seoul, Korea (Mentor: Prof. Yung-Jue Bang)

March 1994 ~ February 2000 (MD)

Graduate Course in College of Medicine, Seoul National University, Seoul, Korea

### Professional Experience

September 2024 ~ present

Professor, Department of Internal Medicine, Seoul National University Boramae Medical Center

March 2016 ~ August 2024

Associate Professor, Department of Internal Medicine, Seoul National University Boramae Medical Center

September 2017 ~ Feb 2018

Visiting Researcher at MRC Cancer Unit/Department of Oncology, University of Cambridge (Director: Dr. Rebecca Fitzgerald)

September 2011 ~ February 2016

### Main Scientific Publications

1. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, Bang YJ, Alcindor T, O'Callaghan C, Strickland A, Rha SY, Lee KW, **Kim JS**, Bai LY, Hara H, Oh DY, Yip S, Zalberg J, Price T, Simes J, Goldstein D. *J Clin Oncol*. 2024 Oct 4
2. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. **Kim JS**, Kim MY, Hong S. *Int J Mol Sci*. 2024 May 29;25(11):5975.



## Frontiers in Digestive Research and Practice

### Main Scientific Publications

3. Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.  
Kim Y, Keam B, Kang EJ, **Kim JS**, Kim HR, Lee KW, Kwon JH, Lee KE, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Choi MY, Lee KH, Kim SB, Ahn MJ. *Cancer Res Treat.* 2024 Oct;56(4):1068-1076. doi: 10.4143/crt.2024.008. Epub 2024 Apr 15.
4. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy.  
Kim D, Kim HJ, Wu HG, Lee JH, Kim S, Kim TM, **Kim JS**, Kim BH. *Cancer Res Treat.* 2024 Apr;56(2):430-441
5. Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection.  
Kim SY, Jeong S, Lee W, Jeon Y, Kim YJ, Park S, Lee D, Go D, Song SH, Lee S, Woo HG, Yoon JK, Park YS, Kim YT, Lee SH, Kim KH, Lim Y, **Kim JS**, Kim HP, Bang D, Kim TY. *Exp Mol Med.* 2023 Nov;55(11):2445-2460.
6. Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo.  
**Kim JS**, Kim MY, Hong S. *Cancers (Basel).* 2023 Sep 28;15(19):4768.
7. Establishment and characterization of BMC-PDC-019: a novel patient-derived cell line of EGFR-mutant pulmonary adenocarcinoma transformed into small-cell lung cancer.  
Kim MY, Jung SY, Hong S, Oh SW, Jin KN, Kim JE, **Kim JS**. *Hum Cell.* 2023 Nov;36(6):2179-2186.
8. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.  
Kim KH, Lim SM, Ahn HK, Lee YG, Lee KW, Ahn MJ, Keam B, Kim HR, Lee HW, An HJ, **Kim JS**. *Cancer Res Treat.* 2024 Jan;56(1):37-47.
9. Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.  
Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, Kim JH, Min YJ, Lee GW, Lee SS, Lee KH, Ko YH, Shim BY, Kim SW, Shin SW, Choi JH, Kim DW, Cho EK, Park KU, **Kim JS**, Chun SH, Wang J, Choi S, Kang JH. *Cancer Res Treat.* 2024 Jan;56(1):48-60.
10. Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer.  
Lee TH, Chung JH, Wu HG, Kim S, Lee JH, Keam B, **Kim JS**, Kim KH, Kim BH, Kim HJ. *Cancer Res Treat.* 2023 Jul;55(3):875-884.